FDAnews
www.fdanews.com/articles/199869-iq-ai-earns-fda-clearance-for-virtual-liver-biopsy-solution

IQ-AI Earns FDA Clearance for Virtual Liver Biopsy Solution

November 5, 2020

IQ-AI has been granted 510(k) marketing clearance from the FDA for its Liver Surface Nodularity software for assessing chronic liver disease patients.

The software’s algorithms process computed tomography images of a patient’s liver to evaluate the nodules along the liver’s surface and to help physicians monitor liver deterioration caused by chronic liver disease.

The noninvasive procedure that uses the software “has the potential to become the standard of care,” IQ-AI said. The company said it will now begin actively marketing the software product in the U.S.

View today's stories